NCT04665310View on ClinicalTrials.gov

Evaluation of Anti-rejection Drug, Tacrolimus, in African-Americans With Kidney Transplant

PHASE4Active, not recruitingINTERVENTIONAL

Enrollment

46

Participants

Timeline

Start Date

September 1, 2018

Primary Completion Date

July 31, 2025

Study Completion Date

October 31, 2025

Conditions

Kidney Disease, End-StageDonor Specific AntibodiesAcute Rejection of Renal Transplant

Interventions

DRUG

Envarsus XR

tacrolimus, extended-release tablets, a calcineurin inhibitor

Sponsors

Collaborators (1)

Veloxis Pharmaceuticals

All Listed Sponsors

collaborator

Veloxis Pharmaceuticals

INDUSTRY

lead

The Methodist Hospital Research Institute

OTHER

NCT04665310 - Evaluation of Anti-rejection Drug, Tacrolimus, in African-Americans With Kidney Transplant | Biotech Hunter | Biotech Hunter